Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Lawrie

Showing results (71-80 of 133) with videos related to

Pageof 14
Sort By:
Circulation|February 13, 2018
Epigenetic Dysregulation of the Dynamin-Related Protein 1 Binding Partners MiD49 and MiD51 Increases Mitotic Mitochondrial Fission and Promotes Pulmonary Arterial Hypertension: Mechanistic and Therapeutic ImplicationsKuang-Hueih Chen, Asish Dasgupta, Jianhui Lin, et al.
Thorax|April 13, 2012
Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosisEmmet E McGrath, Allan Lawrie, Helen M Marriott, et al.
The Journal of Experimental Medicine|October 17, 2012
Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertensionAbdul G Hameed, Nadine D Arnold, Janet Chamberlain, et al.
ERJ Open Research|February 26, 2025
Association of pulmonary hypertension-targeted therapy and survival in precapillary pulmonary hypertension with mean pulmonary arterial pressure between 21 and 24 mmHgAthiththan Yogeswaran, Meike Fünderich, Horst Olschewski, et al.
Pulmonary Circulation|June 13, 2024
Two prospective, multicenter studies for the identification of biomarker signatures for early detection of pulmonary hypertension (PH): The CIPHER and CIPHER-MRI studiesAllan Lawrie, Kelly Chin, Yiu-Lian Fong, et al.
ERJ Open Research|May 19, 2022
Severe pulmonary hypertension associated with lung disease is characterised by a loss of small pulmonary vessels on quantitative computed tomographyDheyaa Alkhanfar, Yousef Shahin, Faisal Alandejani, et al.
Medrxiv : the Preprint Server for Health Sciences|June 5, 2026
Grounding Language Models in Behavioral Science to Scale Physical Activity Interventions for Hispanic/Latinx PopulationsSriya Mantena, Anders Johnson, Narayan Schuetz, et al.
Genes|October 27, 2020
Expression Quantitative Trait Locus Mapping in Pulmonary Arterial HypertensionAnna Ulrich, Pablo Otero-Núñez, John Wharton, et al.
American Journal of Respiratory and Critical Care Medicine|September 14, 2018
Toll-like Receptor 3 Is a Therapeutic Target for Pulmonary HypertensionDaniela Farkas, A A Roger Thompson, Aneel R Bhagwani, et al.
Communications Biology|June 15, 2026
KLF6 activation marks an angiogenic and apoptosis resistant endothelial phenotype in pulmonary arterial hypertensionRehab Alharbi, Merve Keles, Nadia Fernandes, et al.
Pageof 14

Showing results (71-80 of 133) with videos related to

Sort By:
Pageof 14
Circulation|February 13, 2018
Epigenetic Dysregulation of the Dynamin-Related Protein 1 Binding Partners MiD49 and MiD51 Increases Mitotic Mitochondrial Fission and Promotes Pulmonary Arterial Hypertension: Mechanistic and Therapeutic ImplicationsKuang-Hueih Chen, Asish Dasgupta, Jianhui Lin, et al.
Thorax|April 13, 2012
Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosisEmmet E McGrath, Allan Lawrie, Helen M Marriott, et al.
The Journal of Experimental Medicine|October 17, 2012
Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertensionAbdul G Hameed, Nadine D Arnold, Janet Chamberlain, et al.
ERJ Open Research|February 26, 2025
Association of pulmonary hypertension-targeted therapy and survival in precapillary pulmonary hypertension with mean pulmonary arterial pressure between 21 and 24 mmHgAthiththan Yogeswaran, Meike Fünderich, Horst Olschewski, et al.
Pulmonary Circulation|June 13, 2024
Two prospective, multicenter studies for the identification of biomarker signatures for early detection of pulmonary hypertension (PH): The CIPHER and CIPHER-MRI studiesAllan Lawrie, Kelly Chin, Yiu-Lian Fong, et al.
ERJ Open Research|May 19, 2022
Severe pulmonary hypertension associated with lung disease is characterised by a loss of small pulmonary vessels on quantitative computed tomographyDheyaa Alkhanfar, Yousef Shahin, Faisal Alandejani, et al.
Medrxiv : the Preprint Server for Health Sciences|June 5, 2026
Grounding Language Models in Behavioral Science to Scale Physical Activity Interventions for Hispanic/Latinx PopulationsSriya Mantena, Anders Johnson, Narayan Schuetz, et al.
Genes|October 27, 2020
Expression Quantitative Trait Locus Mapping in Pulmonary Arterial HypertensionAnna Ulrich, Pablo Otero-Núñez, John Wharton, et al.
American Journal of Respiratory and Critical Care Medicine|September 14, 2018
Toll-like Receptor 3 Is a Therapeutic Target for Pulmonary HypertensionDaniela Farkas, A A Roger Thompson, Aneel R Bhagwani, et al.
Communications Biology|June 15, 2026
KLF6 activation marks an angiogenic and apoptosis resistant endothelial phenotype in pulmonary arterial hypertensionRehab Alharbi, Merve Keles, Nadia Fernandes, et al.
Pageof 14